Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011, China.
Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing, 210011, China.
Microb Biotechnol. 2019 Nov;12(6):1109-1125. doi: 10.1111/1751-7915.13410. Epub 2019 Apr 21.
Akkermansia muciniphila (A. muciniphila), an intestinal symbiont colonizing in the mucosal layer, is considered to be a promising candidate as probiotics. A. muciniphila is known to have an important value in improving the host metabolic functions and immune responses. Moreover, A. muciniphila may have a value in modifying cancer treatment. However, most of the current researches focus on the correlation between A. muciniphila and diseases, and little is known about the causal relationship between them. Few intervention studies on A. muciniphila are limited to animal experiments, and limited studies have explored its safety and efficacy in humans. Therefore, a critical analysis of the current knowledge in A. muciniphila will play an important foundation for it to be defined as a new beneficial microbe. This article will review the bacteriological characteristics and safety of A. muciniphila, as well as its causal relationship with metabolic disorders, immune diseases and cancer therapy.
黏蛋白阿克曼氏菌(Akkermansia muciniphila,A. muciniphila)是一种定植于黏膜层的肠道共生菌,被认为是一种很有前途的益生菌候选菌。A. muciniphila 被认为在改善宿主代谢功能和免疫反应方面具有重要价值。此外,A. muciniphila 可能在改变癌症治疗方面具有价值。然而,目前的大多数研究都集中在 A. muciniphila 与疾病之间的相关性上,对它们之间的因果关系知之甚少。很少有关于 A. muciniphila 的干预研究仅限于动物实验,并且对其在人类中的安全性和有效性的研究也很有限。因此,对 A. muciniphila 目前知识的批判性分析将为将其定义为一种新的有益微生物奠定重要基础。本文将综述 A. muciniphila 的细菌学特征和安全性,以及其与代谢紊乱、免疫性疾病和癌症治疗的因果关系。